Trial record 14 of 54 for:    "Multiple Sclerosis, Chronic Progressive"

Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Sponsor:
Information provided by (Responsible Party):
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
ClinicalTrials.gov Identifier:
NCT01647321
First received: July 19, 2012
Last updated: September 25, 2013
Last verified: September 2013
  Purpose

Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS) for which there are no existing therapies that alter the disease course. This research will utilize cutting edge functional electrical stimulation (FES) cycling technology with the goal of improving walking in individuals with SPMS. The investigators hypothesize that FES cycling will improve walking in subjects with SPMS.


Condition Intervention Phase
Secondary Progressive Multiple Sclerosis
Behavioral: exercise training
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluating the Effects of Functional Electrical Stimulation on Ambulation in Individuals With Secondary Progressive Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.:

Primary Outcome Measures:
  • Change in timed 25 foot walk from baseline to end of training [ Time Frame: Participants are assessed at baseline (visit 1), one-month (visit 2), two-months (visit 3), three-months (visit 4), end of study (visit 5) ] [ Designated as safety issue: No ]
    Here we will assess whether a subjects walking speed is improved following active cycling with functional electrical stimulation. Our prediction is that individuals will improve in their walking function following seated active cycling with functional electrical stimulation.


Estimated Enrollment: 20
Study Start Date: July 2012
Estimated Study Completion Date: October 2014
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: functional electrical stimulation
Individuals will receive active functional electrical stimulation while on the stationary bike, or their legs will be passively moved while on the stationary bike during the exercise sessions.
Behavioral: exercise training
The exercise program uses a stationary bike equipped with functional electrical stimulation of leg muscles. The training program is expected to be performed for one hour, three times a week for 12 weeks.
Other Names:
  • cycling
  • endurance training

Detailed Description:

Individuals with secondary progressive multiple sclerosis (SPMS) experience significant impairments in ambulation leading to use of canes, walkers, and ultimately wheelchairs. Treatment attempts for progressive MS have been disappointing. No therapeutic intervention has been shown to modulate disability in patients with SPMS. FES cycling has been shown to have multiple primary medical benefits including: increased muscle mass, improvements in bone density, enhanced cardiovascular function, improved bowel function, decreased spasticity and reductions in bladder infection rate. More importantly FES may modulate the inflammatory CNS environment in progressive MS. The investigators are proposing a novel, and easy to implement intervention strategy of FES cycling to help improve gait function in individuals with SPMS. A successful outcome on a larger SPMS population would have significant impact towards changing MS clinical care. FES is easily transferable to clinical practice and could potentially ameliorate other complications associated with SPMS such as spasticity, mood and fatigue reducing the burden of health care cost. In addition, the investigators will gain a better understanding of the mechanisms underlying these changes that could be used to design new therapeutic strategies.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • clinical diagnosis of secondary progressive multiple sclerosis
  • males and females between the ages of 18 and 65 years
  • Expanded disability status scale score between 5.0 and 7.0
  • Able to consent to participate in study and are willing to undergo a lumbar puncture and blood draws
  • If on on Ampyra or anti-spasticity agent, must be on stable dose for 1 month prior to screening
  • No functional electrical stimulation use within 4 weeks
  • Participants must be medically stable with no recent (1 month or less) inpatient admission for acute medical or surgical issues

Exclusion Criteria:

  • Uncontrolled hypertension or other significant cardiovascular disease as determined by investigator
  • History of epileptic seizures
  • Subjects who have a pacemaker
  • Relapse within thirty days prior to screening visit
  • Pregnancy
  • Subjects having a Stage 2 or greater sacral decubitus ulcer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01647321

Contacts
Contact: Shannon Inches 443-923-9235 Inches@kennedykrieger.org

Locations
United States, Maryland
Kennedy Krieger Institute / Johns Hopkins Recruiting
Baltimore, Maryland, United States, 21205
Principal Investigator: K M Zackowski, PhD         
Sponsors and Collaborators
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
  More Information

No publications provided

Responsible Party: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
ClinicalTrials.gov Identifier: NCT01647321     History of Changes
Other Study ID Numbers: NA_00069253
Study First Received: July 19, 2012
Last Updated: September 25, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Hugo W. Moser Research Institute at Kennedy Krieger, Inc.:
SPMS

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Multiple Sclerosis, Chronic Progressive
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on August 21, 2014